Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 8.96M | $127.0M | 14.59% | -- | 2026-03-31 |
| MPM BIOIMPACT LLC | 7.65M | $108.0M | 12.45% | -- | 2026-03-31 |
| BVF INC/IL | 5.75M | $81.0M | 9.36% | -- | 2026-03-31 |
| BlackRock, Inc. | 4.45M | $63.0M | 7.24% | +49.7K | 2026-03-31 |
| Kynam Capital Management, LP | 3.11M | $44.0M | 5.07% | -- | 2026-03-31 |
| STATE STREET CORP | 2.54M | $36.0M | 4.14% | +346.8K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.48M | $35.0M | 4.04% | -- | 2026-03-31 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.03M | $28.0M | 3.30% | +1.98M | 2026-03-31 |
| Blue Owl Capital Holdings LP | 1.91M | $27.0M | 3.11% | -441.2K | 2026-03-31 |
| RTW INVESTMENTS, LP | 1.71M | $24.0M | 2.78% | -- | 2026-03-31 |
